Cookie use on MRCVSonline
We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive all cookies.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

Study highlights scale of field trials for bovine TB vaccine
As many as 100,000 cattle would be needed to show the effect of a vaccine on bTB transmission.
Researchers propose smaller, natural transmission experiments

New research has highlighted the cost and scale of field trials for bovine TB (bTB).

Writing in the journal eLife, researchers show that as many as 100,000 cattle would be needed to show the effect of a vaccine on bTB transmission. They suggest that this scale and cost could be dramatically reduced by using smaller, less expensive experiments.

“We already know that the BCG vaccine has the potential to protect cattle from bovine TB infection,” explains first author Dr Andrew Conlan from the University of Cambridge’s department of veterinary medicine. “Our results highlight the enormous scale of trials that would be necessary to evaluate BCG alongside continuing testing in the field.

“Such trials would be hugely expensive, and it isn’t even clear whether enough farms could be recruited.”

The researchers propose a natural transmission experiment that involves housing a mixture of vaccinated and unvaccinated cattle with a number of infected cattle. They argue that such an experiment could show the efficacy of vaccination, using as little as 200 cattle.

In the UK, the bTB strategy is to ‘test and slaughter’ infected animals. Whilst the BCG vaccine does exist, it can cause some cattle to test positive falsely.

The BCG vaccine is currently banned in Europe. However, the European Union has stated that it would consider relaxing its laws if the UK government could show that a vaccine is effective on farms.

“If we could consider replacing test-and-slaughter with vaccination, then the economics becomes much more attractive particularly in lower income countries,” explained professor James Wood, head of Cambridge’s department of veterinary medicine.

“Then we would no longer need to carry out expensive testing, but could instead rely on passive surveillance through the slaughterhouses.”

Become a member or log in to add this story to your CPD history

New single-dose RHD-2 vaccine launched

News Story 1
 The first monovalent vaccine to be registered in Europe for the prevention of rabbit hemorrhagic disease type 2 (RHD-2) has been launched by animal health firm HIPRA.

ERAVAC is a single-dose injectable emulsion that can be administered without the need for reconstitution beforehand. The new presentation contains 10 vials with individual doses that can be given to companion rabbits from 30 days of age. 

Click here for more...
News Shorts
New canine and feline dentistry manual announced

A new canine and feline dentistry and oral surgery manual has been published by the BSAVA. Announcing the news on its website, the BSAVA said this latest edition contains new step-by-step operative techniques, together with full-colour illustrations and photographs.

‘This is a timely publication; veterinary dentistry is a field that continues to grow in importance for the general veterinary practitioner,’ the BSAVA said. ‘The manual has been fully revised and updated to include the most relevant, evidence-based techniques.’

The BSAVA Manual of Canine and Feline Dentistry and Oral Surgery, 4th edition is available to purchase from www.bsava.com/shop